PensionDanmark Pensionsforsikringsaktieselskab Buys 3,040 Shares of Stryker Corporation $SYK

PensionDanmark Pensionsforsikringsaktieselskab lifted its stake in shares of Stryker Corporation (NYSE:SYK) by 4.7% during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 68,326 shares of the medical technology company’s stock after buying an additional 3,040 shares during the period. PensionDanmark Pensionsforsikringsaktieselskab’s holdings in Stryker were worth $21,512,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of SYK. VanderPol Investments L.L.C. lifted its stake in Stryker by 1.4% during the 4th quarter. VanderPol Investments L.L.C. now owns 2,084 shares of the medical technology company’s stock valued at $732,000 after acquiring an additional 28 shares in the last quarter. KCM Investment Advisors LLC raised its holdings in shares of Stryker by 1.5% in the fourth quarter. KCM Investment Advisors LLC now owns 1,857 shares of the medical technology company’s stock valued at $653,000 after purchasing an additional 28 shares during the last quarter. Rossby Financial LCC lifted its position in shares of Stryker by 6.6% during the fourth quarter. Rossby Financial LCC now owns 451 shares of the medical technology company’s stock valued at $159,000 after purchasing an additional 28 shares in the last quarter. Tcfg Wealth Management LLC boosted its holdings in Stryker by 2.7% during the third quarter. Tcfg Wealth Management LLC now owns 1,091 shares of the medical technology company’s stock worth $403,000 after purchasing an additional 29 shares during the last quarter. Finally, Mechanics Financial Corp boosted its holdings in Stryker by 1.2% during the fourth quarter. Mechanics Financial Corp now owns 2,458 shares of the medical technology company’s stock worth $864,000 after purchasing an additional 30 shares during the last quarter. 77.09% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Stryker

In other news, VP M Kathryn Fink sold 5,220 shares of the company’s stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total transaction of $1,481,697.00. Following the transaction, the vice president owned 13,137 shares of the company’s stock, valued at $3,728,937.45. This represents a 28.44% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total value of $96,791,300.00. Following the transaction, the director owned 1,924,880 shares of the company’s stock, valued at $601,005,282.40. The trade was a 13.87% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Price Performance

SYK opened at $336.91 on Friday. Stryker Corporation has a fifty-two week low of $281.00 and a fifty-two week high of $396.86. The firm has a 50-day moving average of $319.45 and a 200 day moving average of $334.10. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The firm has a market cap of $129.23 billion, a P/E ratio of 34.91, a PEG ratio of 2.15 and a beta of 0.76.

Stryker (NYSE:SYK) last announced its quarterly earnings data on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping the consensus estimate of $3.49 by $0.20. The business had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The company’s revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 15.02 EPS for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s payout ratio is 36.48%.

Wall Street Analysts Forecast Growth

SYK has been the subject of several analyst reports. The Goldman Sachs Group reiterated a “neutral” rating and issued a $361.00 price objective on shares of Stryker in a research note on Friday, May 1st. Wolfe Research set a $375.00 target price on Stryker in a research note on Friday, July 31st. BMO Capital Markets began coverage on Stryker in a report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 target price for the company. Leerink Partners decreased their price target on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a research report on Friday, June 5th. Finally, Canaccord Genuity Group dropped their price target on Stryker from $435.00 to $400.00 and set a “buy” rating on the stock in a report on Friday, May 1st. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and five have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $386.28.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.